Resverlogix Corp (RVX) Common NPV

Resverlogix Corp. is a Canada-based late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. The Company focuses on the development of a new class of therapeutics: bromodomain and extraterminal domain (BET) protein inhibitors. BET proteins play a central role in epigenetics and enable the transcription of disease-causing genes. Its small molecule BET inhibitors are designed to exploit this central epigenetic role to regulate gene expression and tackle the root causes of chronic diseases. The Company's clinical program focuses on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post-COVID-19 conditions. It partners with EVERSANA to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.